See the published version of this preprint at Applied Biochemistry and Biotechnology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Olfa Tabbene
Centre de Biotechnologie de Borj-Cédria
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
A strain B84 producing surfactin and bacillomycin D lipopeptides was identified as Bacillus amyloliquefaciens. B84 lipopeptides were extracted by acid precipitation, identified by mass spectrometry and loaded onto chitosan nanoparticles by ionotropic gelation process. The lipopeptide / chitosan nanoparticles have an average size of 569 nm, a zeta potential range of 38.8 mV and encapsulation efficiency (EE) of 85.58 %. The treatment of C. albicans cells with encapsulated lipopeptides showed an anti-adhesive activity of 81.17 % and a decreased effect of cell surface hydrophobicity « CSH » by 25.53%. An anti-leishmanial activity was also recorded with IC50 of 14.37 µg ml-1 and 22.45 µg mL-1 against L. major promastigote and amastigote forms, respectively. Cytotoxicity studies on human cells showed low cytotoxicity effect with HC50 value of 770 µg mL-1 towards human red blood cells and LC50 value of 234.56 µg mL-1 towards macrophage Raw 264.7 cell line. These lipopeptide / chitosan nanoparticles could be used as a potential delivery system of lipopeptides to improve both their anti-adhesive effect against C. albicans cells colonizing medical devices and their anti-infectious activity against leishmania.
Keywords
Chitosan, nanoparticles, lipopeptides, anti-adhesive, antileishmanial
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Applied Biochemistry and Biotechnology.
Version 1
Posted 19 Mar, 2021
No community comments so far
Reviewers invited
Invitations sent on 02 Apr, 2021
Reviews received
Received 15 Mar, 2021
Editor invited
On 14 Mar, 2021
First submitted
On 12 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Biotechnology and Bioengineering
Learn more about our company.
See the published version of this preprint at Applied Biochemistry and Biotechnology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Olfa Tabbene
Centre de Biotechnologie de Borj-Cédria
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Applied Biochemistry and Biotechnology.
Version 1
Posted 19 Mar, 2021
No community comments so far
Reviewers invited
Invitations sent on 02 Apr, 2021
Reviews received
Received 15 Mar, 2021
Editor invited
On 14 Mar, 2021
First submitted
On 12 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Biotechnology and Bioengineering
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Applied Biochemistry and Biotechnology.
A strain B84 producing surfactin and bacillomycin D lipopeptides was identified as Bacillus amyloliquefaciens. B84 lipopeptides were extracted by acid precipitation, identified by mass spectrometry and loaded onto chitosan nanoparticles by ionotropic gelation process. The lipopeptide / chitosan nanoparticles have an average size of 569 nm, a zeta potential range of 38.8 mV and encapsulation efficiency (EE) of 85.58 %. The treatment of C. albicans cells with encapsulated lipopeptides showed an anti-adhesive activity of 81.17 % and a decreased effect of cell surface hydrophobicity « CSH » by 25.53%. An anti-leishmanial activity was also recorded with IC50 of 14.37 µg ml-1 and 22.45 µg mL-1 against L. major promastigote and amastigote forms, respectively. Cytotoxicity studies on human cells showed low cytotoxicity effect with HC50 value of 770 µg mL-1 towards human red blood cells and LC50 value of 234.56 µg mL-1 towards macrophage Raw 264.7 cell line. These lipopeptide / chitosan nanoparticles could be used as a potential delivery system of lipopeptides to improve both their anti-adhesive effect against C. albicans cells colonizing medical devices and their anti-infectious activity against leishmania.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...